南新制药
(688189)
| 流通市值：22.23亿 | | | 总市值：22.23亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 40,624,818.43 | 263,284,800.95 | 251,110,585.69 | 215,327,140.5 |
| 营业收入 | 40,624,818.43 | 263,284,800.95 | 251,110,585.69 | 215,327,140.5 |
| 二、营业总成本 | 47,665,234.41 | 328,725,287.15 | 221,340,831.77 | 153,579,478.34 |
| 营业成本 | 19,500,318.95 | 119,555,045.75 | 98,540,854.18 | 78,192,362.12 |
| 税金及附加 | 651,355.19 | 4,872,018.12 | 4,367,727.64 | 3,711,317.92 |
| 销售费用 | 7,116,773.68 | 107,735,297.69 | 64,474,681.29 | 42,495,673.81 |
| 管理费用 | 9,475,797.47 | 49,214,286.47 | 28,405,688.91 | 15,805,362.42 |
| 研发费用 | 10,420,828.81 | 48,807,332.82 | 26,325,369.38 | 14,799,006.3 |
| 财务费用 | 500,160.31 | -1,458,693.7 | -773,489.63 | -1,424,244.23 |
| 其中:利息费用 | 1,239,472.21 | 5,401,505.42 | 3,536,656.5 | 2,577,462.05 |
| 其中:利息收入 | 717,396.82 | 6,973,543.55 | 5,454,544.72 | 5,100,712.72 |
| 资产处置收益 | - | 594,628.23 | - | - |
| 资产减值损失(新) | -875,547.7 | -41,297,260.04 | -2,780,228.97 | -2,899,873.3 |
| 信用减值损失(新) | -444,442.19 | -283,696,828.82 | -93,802,005 | -46,723,615.56 |
| 其他收益 | - | 1,776,230.06 | - | - |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -8,360,405.87 | -388,063,716.77 | -66,812,480.05 | 12,124,173.3 |
| 加:营业外收入 | 303,555.8 | 83,264.89 | 1,388,539.67 | 1,212,681.32 |
| 减:营业外支出 | 10,151.54 | 656,606.92 | 645,528.7 | 535,326 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -8,067,001.61 | -388,637,058.8 | -66,069,469.08 | 12,801,528.62 |
| 减:所得税费用 | 34,507.62 | 8,636,797.03 | -144,036.72 | 1,689,404.19 |
| 六、净利润 | -8,101,509.23 | -397,273,855.83 | -65,925,432.36 | 11,112,124.43 |
| 持续经营净利润 | -8,101,509.23 | -397,273,855.83 | -65,925,432.36 | 11,112,124.43 |
| 归属于母公司股东的净利润 | -8,028,308.26 | -356,903,643.41 | -57,215,916.93 | 10,172,683.21 |
| 少数股东损益 | -73,200.97 | -40,370,212.42 | -8,709,515.43 | 939,441.22 |
| (一)基本每股收益 | -0.03 | -1.3 | -0.21 | 0.04 |
| (二)稀释每股收益 | -0.03 | -1.3 | -0.21 | 0.04 |
| 九、综合收益总额 | -8,101,509.23 | -397,273,855.83 | -65,925,432.36 | 11,112,124.43 |
| 归属于母公司股东的综合收益总额 | -8,028,308.26 | -356,903,643.41 | -57,215,916.93 | 10,172,683.21 |
| 归属于少数股东的综合收益总额 | -73,200.97 | -40,370,212.42 | -8,709,515.43 | 939,441.22 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |